Comparative Pharmacology
Head-to-head clinical analysis: RIFAXIMIN versus XEPI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIFAXIMIN versus XEPI.
RIFAXIMIN vs XEPI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rifaximin is a non-aminoglycoside, semi-synthetic antibiotic derived from rifamycin that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby blocking transcription.
Ozenoxacin is a topical fluoroquinolone antibiotic that inhibits bacterial DNA replication by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to cell death.
550 mg orally three times daily for 14 days for travelers' diarrhea; 200 mg orally three times daily for 3 days for irritable bowel syndrome with diarrhea; 400 mg orally three times daily for 7 days for hepatic encephalopathy.
Topical: Apply a pea-sized amount to the affected area twice daily. For moderate to severe plaque psoriasis, initiate treatment with clobetasol propionate spray 0.05% applied twice weekly (Sunday and Thursday) to the scalp and/or body lesions. For plaque psoriasis under occlusion or on limited areas, clobetasol propionate foam 0.05% applied twice daily. For scalp psoriasis, clobetasol propionate shampoo 0.05% applied once daily to the dry scalp, left for 15 minutes, then rinsed. For steroid-responsive dermatoses, clobetasol propionate ointment, cream, or lotion 0.05% applied sparingly to the affected area twice daily (morning and night) for up to 2 weeks; re-evaluate if no improvement. Maximum dose: 50 g/week of 0.05% preparation; for scalp applications, 50 mL/week.
Clinical Note
moderateRifaximin + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Tranilast
MODERATE Risk
MODERATE Risk
The terminal elimination half-life is approximately 1.8 to 2.5 hours in patients with normal hepatic function. Due to negligible systemic absorption, the half-life has limited clinical relevance; drug action is largely confined to the gastrointestinal tract.
Terminal elimination half-life is approximately 8 hours in patients with normal renal function (creatinine clearance ≥90 mL/min). In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to about 15 hours.
Rifaximin is primarily eliminated in feces as unchanged drug (>96% of an oral dose). Renal excretion is negligible (<0.4%). Biliary excretion is minimal due to poor systemic absorption.
Approximately 80% eliminated renally as unchanged drug via glomerular filtration and tubular secretion. Approximately 20% eliminated in feces via biliary excretion.
Category A/B
Category C
Antibiotic
Antibiotic
"The serum concentration of Tranilast can be decreased when it is combined with Rifaximin."